[1]陈俊良,孙志卫,王健宇,等.miR200c过表达对寡灶型转移细胞株体外特性的影响[J].第三军医大学学报,2016,38(23):2486-2491.
 Chen Junliang,Sun Zhiwei,Wang Jianyu,et al.Effect of miR200c over-expression on biological features of oligometastatic cells in vitro[J].J Third Mil Med Univ,2016,38(23):2486-2491.
点击复制

miR200c过表达对寡灶型转移细胞株体外特性的影响(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
38卷
期数:
2016年第23期
页码:
2486-2491
栏目:
基础医学
出版日期:
2016-12-15

文章信息/Info

Title:
Effect of miR200c over-expression on biological features of oligometastatic cells in vitro
作者:
陈俊良孙志卫王健宇邢若曦
重庆医科大学生命科学研究院
Author(s):
Chen Junliang Sun Zhiwei Wang Jianyu Xing Ruoxi

Life Sciences Institute, Chongqing Medical University, Chongqing, 400016, China

关键词:
miR200c寡灶转移多灶转移
Keywords:
miR200c oligometastasis polymetastasis
分类号:
R394.3; R73354; R730.23
文献标志码:
A
摘要:

目的     探索miR200c稳定过表达对寡灶型转移肿瘤细胞株体外癌症生物学特性的影响。方法     通过慢病毒感染建立稳定上调miR200c表达的寡灶型转移细胞株MDA-435-OL-miR200c(实验组),并同时建立阴性对照组(感染空质粒LV3NC)和阳性对照组(多灶型细胞株MDA-435-POL),通过CCK-8增殖曲线测定、琼脂平板克隆实验、Transwell小室迁移和侵袭实验来阐明上调miR200c对寡灶型转移细胞体外特性的影响以及上调目的基因后寡灶型与多灶型转移细胞株体外癌症生物学特性的不同和联系。 结果     在稳定寡灶转移细胞株中过表达miR200c对细胞体外克隆形成率为(0.69±0.02),迁移细胞数为(21.20±2.35),侵袭细胞数为(56.80±5.22),均较阴性对照组显著增加(P<0.05),与阳性对照组体外特性基本一致。但miR200c过表达对增殖能力没有显著的影响。 结论     寡灶型细胞株稳定上调miR200c后体外克隆形成能力、迁移能力和侵袭能力均有所提高,且呈现出多灶型细胞株的特性。

Abstract:

Objective      To determine the effect of stable miR200c over-expression on the cancer biological features of the oligometastatic cells in vitro.  MethodsAn oligometastatic cell line over-expressing miR200c was established by lentivirus infection (MDA-435-OL-miR200c). At the same time, a negative control cell line was generated by transfection with empty plasmid LV3NC. MDA-435-POL line, with confirmed polymetastatic phenotype in vivo served as a positive control for this study. The biological effect of miR200c over-expression was evaluated by CCK-8 assay for cell proliferation, agar colony formation assay for clonogeneicity, transwell migration assay and matrigel invasion assay for the invasiveness.  Results      Over-expression of miR200c resulted in the increases in the clonogenicity (cloning efficiency: 0.69±0.02), cell migration (migrated cells number: 21.20±2.35) and invasion ability (invasive cells number: 56.80±5.22), in the oligometastatic MDA-435-OL cells, and all the parameters were significantly higher than those of negative control (P<0.05) and were similar to those of positive control. However, the miR200c over-expression had no effect on cell proliferation.   Conclusion      Stable over-expression of miR200c results in increases in clonogenicity, cell migration and invasion ability in the oligometastatic MDA-435-OL cells, which are resemble to those of MDA-435-POL polymetastatic cells.

参考文献/References:

[1]Weichselbaum R R,  Hellman S. Oligometastasesrevisited[J]. Nat Rev Clin Oncol, 2011, 8(6): 378-382.DOI:  10.1038/nrclinonc.2011.44
[2]Hellman S,  Weichselbaum R R. Oligometastases[J]. J ClinOncol, 1995, 13(1): 8-10.
[3]Staren E D,  Salerno C,  Rongione A,  et al. Pulmonary resection for metastatic breast cancer[J]. Arch Surg, 1992, 127(11): 1282-1284.
[4]Tomlinson J S,  Jarnagin W R,  DeMatteo R P,  et al. Actual 10year survival after resection of colorectal liver metastases defines cure[J]. J Clin Oncol, 2007, 25(29): 4575-4580.DOI: 10.1200/JCO.2007.11.0833
[5]Fong Y,  Cohen A M,  Fortner J G,  et al. Liver resection for colorectal metastases[J]. J Clin Oncol, 1997, 15(3): 938-946.
[6]Salama J K,  Chmura S J,  Mehta N,  et al. An initial report of a radiation doseescalation trial in patients with one to five sites of metastatic disease[J]. Clin Cancer Res, 2008, 14(16): 5255-5259.DOI: 10.1158/10780432.CCR-08-0358
[7]Wong A C,  Watson S P,  Pitroda S P,  et al. Clinical and molecular markers of longterm survival after oligometastasisdirected stereotactic body radiotherapy (SBRT) [J]. Cancer, 2016 , 122(14): 2242-2250. DOI:  10.1002/cncr.30058
[8]Suzuki H,  Yoshino I. Approach for oligometastasis in non-small cell lung cancer[J]. Gen Thorac Cardiovasc Surg,  2016 , 64(4): 192-196. DOI:  10.1007/s11748-016-0630-7
[9]Hishida T,  Yoshida J,  Aokage K,  et al.Postoperative oligorecurrence of nonsmallcell lung cancer:  Clinical features and survival[J]. Eur J Cardiothorac Surg,  2016 , 49(3): 847-853. DOI:  10.1093/ejcts/ezv249
[10]Lussier Y A,  Xing H R,  Salama J K,  et al. microRNA expression characterizes oligometastasis[J]. PLoS One, 2011,  6(12):  e28650. DOI: 10.1371/journal.pone.0028650
[11]Selzner M,  Morse M A,  Vredenburgh J J,  et al.Liver metastases from breast cancer:  longterm survival after curative resection[J].Surgery, 2000, 127(4): 383-389.
[12]Tanvetyanon T,  Robinson L A,  Schell M J,  et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer:  a systematic review and pooled analysis[J]. J Clin Oncol, 2008, 26(7): 1142-1147.DOI: 10.1200/JCO. 2007.14.2091
[13]Milano M T,  Katz A W,  Muhs A G,  et al.A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions[J].  Cancer, 2008, 112(3): 650-658.DOI: 10.1002/cncr.23209
[14]Rusthoven K E,  Kavanagh B D,  Burri S H, et al. Multi-institutional phase Ⅰ/Ⅱ trial of stereotactic body radiation therapy for lung metastases[J].  J Clin Oncol, 2009, 27(10): 1579-1584.DOI: 10.1200/JCO.2008.19.6386
[15]Norihisa,  Y Nagata Y,  Takayama K,  et al. Stereotactic body radiotherapy for oligometastatic lung tumors[J].  Int J Radiat Oncol Biol Phys, 2008, 72(2): 398-403. DOI: 10.1016/j.ijrobp.2008.01.002
[16]Hoyer M,  Roed H,  Traberg Hansen A,  et al. Phase Ⅱ study on stereotactic body radiotherapy of colorectal metastases[J].  Acta Oncol, 2006, 45(7): 823-830. DOI: 10.1080/02841860600904854
[17]Lussier Y A,  Khodarev N N,  Regan K,  et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs[J]. PLoS One, 2012, 7(12): e50141. DOI:  10.1371/journal.pone.0050141
[18]Uppal A,  Wightman S C,  Mallon S,  et al. 14q32-encoded microRNAs mediate an oligometastatic phenotype[J]. Oncotarget, 2015, 6(6): 3540-3552.DOI:  10.18632/ oncotarget.2920
[19]Uppal A,  Ferguson M K,  Posner M C. et al. Towards a molecular basis of oligometastatic disease:  potential role of micro-RNAs[J]. Clin Exp Metastasis, 2014, 31(6):  735-748. DOI :  10.1007/s10585-014-9664-3
[20]Formosa A,  Markert E K,  Lena A M. et al. MicroRNAs,  miR-154,  miR-299-5p,  miR-376a,  miR-376c,  miR-377,  miR-381,  miR-487b,  miR-485-3p,  miR-495 and miR-654-3p,  mapped to the 14q32.31 locus,  regulate proliferation,  apoptosis,  migration and invasion in metastatic prostate cancer cells[J]. Oncogene, 2014, 33(44): 5173-5182. DOI:  10.1038/onc.2013.451
[21]Bendoraite A,  Knouf E C,  Garg K S,  et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer:  evidence supporting a mesothelial to epithelial transition[J]. Gynecol Oncol,  2010, 116(1): 117-125.DOI: 10.1016/j.ygyno.2009.08.009
[22]Korpal M,  Lee E S,  Hu G,  et al. The miR-200 family inhibits epithelialmesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2[J]. J Biol Chem, 2008, 283(22): 14910-14914.DOI: 10.1074/jbc.C800074200
[23]Gregory P A,  Bert A G,  Paterson E L,  et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1[J]. Nat Cell Biol, 2008, 10(5): 593-601.DOI: 10.1038/ncb1722
[24]ElsonSchwab I,  Lorentzen A,  Marshall C J. MicroRNA200 family members differentially regulate morphological plasticity and mode of melanoma cell invasion[J]. PLoS One, 2010, 5(10):  e13176. DOI:  10.1371/journal.pone.0013176
[25]Korpal M,  Ell B J,  Buffa F M,  et al. Direct targeting of Sec23a by miR200s influences cancer cell secretome and promotes metastatic colonization[J]. Nat Med, 2011, 17(9): 1101-1108.DOI:  10.1038/nm.2401
[26]Bonnomet A,  Brysse A,  Tachsidis A,  et al. Epithelial to mesenchymal transitions and circulating tumor cells[J]. J Mammary Gland Biol Neoplasia, 2010, 15(2): 261-273.DOI: 10.1007/s10911-010-9174-0

更新日期/Last Update: 2016-12-05